AstraZeneca/AZN

-0.85%
-
1D1W1MYTD1YMAX

About AstraZeneca

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

Ticker

AZN

Sector

Healthcare

Trading on

LSE

Industry

Biotechnology & Drugs

CEO

Pascal Soriot

Employees

89,900

Headquarters

Cambridge, United Kingdom

AstraZeneca Metrics

BasicAdvanced
£210.58B
Market cap
35.61
P/E ratio
£3.81
EPS
0.34
Beta
£2.90
Dividend rate
2.09%
Dividend yield
£210.58B
0.34213
£153.55
£117.42
2.84M
£2.90
0.82
0.643
59.326
73.122
75.513
6.34%
6.03%
15.63%
8.47%
35.614
4.597
5.379
100.947
2.44%
2.13%
2.09%
4.1%
100.69%
19.84%
16.13%
0.81%

What the Analysts think about AstraZeneca

Analyst Ratings

Majority rating from 28 analysts.
Buy

Price Targets

Average projection from 24 analysts.
14.39% upside
High £176.75
Low £64.30
£109.46
Current price
£125.21
Average price target

AstraZeneca Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
7.98% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$12.02B
4.63%
Net income
$960M
-30.13%
Profit margin
7.98%
-33.22%

AstraZeneca Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.82%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$1.92
$2.15
$1.73
$1.45
-
Expected
$1.71
$1.95
$1.62
$1.49
$1.93
Surprise
12.03%
10.01%
6.92%
-2.82%
-
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and LSEG. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for AstraZeneca stock?

AstraZeneca (AZN) has a market cap of £210.58B as of April 20, 2024.

What is the P/E ratio for AstraZeneca stock?

The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 35.61 as of April 20, 2024.

Does AstraZeneca stock pay dividends?

Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of April 20, 2024, the dividend rate is £2.89787 and the yield is 2.09%. AstraZeneca has a payout ratio of 0% on a trailing twelve-month basis.

When is the next AstraZeneca dividend payment date?

The next AstraZeneca (AZN) dividend payment date is unconfirmed.

What is the beta indicator for AstraZeneca?

AstraZeneca (AZN) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the AstraZeneca stock price target?

The target price for AstraZeneca (AZN) stock is £125.95, which is 15.06% above the current price of £109.46. This is an average based on projections from 24 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell AstraZeneca stock

Buy or sell AstraZeneca stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing